95 results about "Prostatic Gland" patented technology

The invention provides a robot for aspiration biopsy of the prostatic gland, which is the prostatic aspiration biopsy equipment providing a cytologic diagnosis evidence for early-stage prostate cancer. The equipment comprises a computer system(1) for receiving and processing prostatic ultrasonograph data, a Motoman robot(3), a puncturing mechanism(4) and a driving device for a motor(6) of the puncturing mechanism(4), wherein the puncturing mechanism(4) is an end effector of the robot(3) and fixed at the tail end of the robot(3); the puncturing mechanism(4) consists of a DC servo motor(6), a base, two guide rails(7), a V-shaped belt(8), a front-end bearing seat(9), a needle-holding seat(10) and an electromagnetic launching device; the DC servo motor(6) is connected with the seat and can be disassembled by a V-shaped belt tightener (13); and the seat is arranged on the two guide rails(7) and connected with the V-shaped belt(8) by a belt clamping device(15). The robot can realize the accurate positioning, high efficiency, automation and informatization in a diagnostic process, so that the labor intensity of doctors is greatly lowered.

The invention provides a built-in catheter. The built-in catheter comprises a catheter body and a control valve, wherein the inside of the catheter body is hollow and serves as a urine guide cavity, one end of the catheter body is provided with a urine inlet, the other end of the catheter body is provided with a urine outlet, the catheter body comprises a partes prostatica part, a membranous partand a bulb part, the control valve is positioned inside the urine guide cavity and is used for controlling the on-off state of the urine guide cavity, in order to enable the catheter body to be stablyfixed inside the male urethra, the partes prostatica part is provided with a partes prostatica bulge, the bulb part is provided with a bulb bulge, the membranous part is provided with a membranous sinking part, the partes prostatica bulge, the bulb bulge and the membranous sinking part between the partes prostatica bulge and the bulb bulge are bent-dumbbell-shaped in the male urethra, thus the front-back movement of the catheter body can be prevented, and meanwhile, the interference pressing for the neck of the male bladder and the urethra can be eliminated.

Parametrical analysis of uroflowmetry test results to identify urological disorders particularly to distinguish men who have low urinary tract disorder/benign prostatic hyperplasia from those who have overactive bladder. Primary urine flow dynamic parameters and secondary urine flow dynamic parameters are calculated. Patient's urological disorders can be assessed by comparing the primary and secondary urine flow dynamic parameters with a library or database of comparable data derived from healthy or normal individuals as well as comparable data derived from individuals afflicted with specific urological disorders. A predictive model of lower urinary tract function disorders can be developed from existing reference primary and secondary urine flow dynamic parameters. The model allows for complex analysis and objective disease prediction.

The invention provides a method for testing prostate-fluid free heme. The method comprises the following steps: obtaining prostate-fluid seepage fluid; processing the seepage fluid with a trismetyl aminomethane-hydrochloric acid buffer solution with the PH being 7.4; and reacting with a color reagent, comparing with a shade guide, and recording test results. The method is simple and practical, is low in cost, and can rapidly screen samples without heme, samples with heme, and samples probably containing heme in cervical seepage fluid to make preparations for further screening. Meanwhile, the invention also relates to a test kit for testing prostate-fluid seepage fluid.

Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

To perform pelvic surgery, a directionally illuminating balloon catheter enters a bladder. The catheter has a multi-lumen shaft. The balloon defines an interior fluidically connected to a balloon inflation lumen and is inflated therethrough. The balloon comprises a light source, a light-radiating surface adjacent the shaft-balloon junction, and a substantially opaque surface disposed at a portion of the balloon other than the light-radiating surface such that the integrated light source illuminates a distal half of the environment outside the balloon. The balloon is inflated while in the bladder. Light from the light source is directed out through the light-radiating surface to illuminate at least a portion of a procedure area opposite the bladder-prostate junction. With the light illuminating the portion of the procedure area, at least a portion of a pelvic surgery is performed at the portion of the procedure area.

The invention discloses a magnetic probe steel assembly for urethral reunion operation. The magnetic probe steel assembly comprises first probe steel and second steel, wherein two ends of the first probe steel are a first handheld end and a first magnetic end; the first magnetic end is used for extending in from anterior urethra, passing through a bulb of urethra part and arriving at a membranousurethra breaking position; the end of the first magnetic end has magnetism; a channel allowing a guide wire to pass through is formed in an inner cavity of the first probe steel along the direction ofthe first probe steel; two ends of the second probe steel are a second handheld end and a second magnetic end; the second magnetic end is used for entering prostatic urethra through bladder and arriving at the membranous urethra breaking position; and the end of the second magnetic end has magnetism. According to the magnetic probe steel assembly disclosed by the invention, through cooperation ofthe first probe steel and the second probe steel, an operator is convenient to operate; and through mutual attraction of the first magnetic end and the second magnetic end, the situation that under the attraction of the second probe steel, the first probe steel enters the bladder, and urethral reunion operation is completed is guaranteed.

The invention discloses a urine nucleic acid maker and detection reagent kit for assisting in early screening of prostatic cancer. The nucleic acid marker comprises three prostatic cancer related genes of a T2E fusion gene, a PCA3 gene and an MMP-2 gene, and two internal reference genes of a PSA gene and an SPDEF gene. A multiple fluorescence reverse transcription polymerase chain reaction (RT-PCR) detection reagent comprising the five nucleic acid markers can be used for assisting in screening of prostatic cancer, an area under curve (AUC) of a testee operating characteristic (ROC) curve canachieve 0.81, and sensitivity predicted value and negative predicted value are respectively as high as 91.6% and 93.3%. The detection reagent kit is simple to operate, and quantitative detection of the nucleic acid markers and screening of the prostatic cancer can be completed in one pipe of the reagent. Unnecessary puncturing inspection of prostate can be notably reduced, and the reagent kit hasfavorable clinical application prospects.

The invention provides a male chronic prostatitis/chronic pelvic pain syndrome pain severity prediction model and establishment thereof, and relates to the field of chronic prostatitis/chronic pelvicpain syndrome pain severity prediction. The pain severity prediction model is established by adopting an advantage ratio OR of variables such as the age of a patient, the level of lecithin bodies in prostatic fluid, urine suppression, anxiety or irritability, contraception, smoking and the like, establishing a column diagram as a model to predict the pain severity of the CP/CPPS patient on the basis of the confidence intervals of 2.5% and 97.5% and the P-value. Establishment of the model mainly comprises the steps of material selection, grouping, variable screening, variable analysis and the like. According to the method, the defects in the prior art are overcome, the pain level of prostatitis can be accurately predicted by establishing the model, and meanwhile, the clinical decision-making efficiency is improved.

Aspects of the present invention relate to a method for locating an expandable implant for treating BPH within the prostatic urethra of a patient. The delivery device comprises an inner tube and an outer sleeve moveable relative to the inner tube between a stored position and a deployed position. The outer sleeve surrounds the inner tube to define an annulus therebetween and the expandable implant is retained within the annulus when the outer sleeve is in the stored position.

The invention provides application of periplaneta Americana to preparation of a medicine for treating prostatitis. The medicine can reduce the WBC content in prostatic fluid of prostatitis patients and decrease inflammatory factors in prostatic fluid of the prostatitis patients, and prostatitis refers to IIIA prostatitis. The medicine contains a periplaneta Americana extract, levofloxacin and tamsulosin which are simultaneously or separately fed. Clinical test results show that the medicine has the clinical effective rate of up to 73.53% on IIIA prostatitis patients, and can remarkably reduce contents of WBC, TNF-alpha and IL-10 in prostatic fluid of the IIIA prostatitis patients.

The invention belongs to the technical field of medical instruments, and particularly relates to a prostate removing endoscope. The prostate removing endoscope comprises a guide cannula; threaded tubethreads are connected into the guide cannula in a threaded mode, and a supporting tube is fixed into a threaded tube; medical pull ropes are inserted into the circumferential inner wall of the supporting tube; the outer wall of the threaded tube is in threaded connection with a threaded rotary disc, and the end face of the threaded rotary disc is rotationally connected with a plurality of medicalpull ropes through rotary rings; a conical umbrella cap is fixed to the end of the supporting tube and formed by splicing a plurality of arc-shaped silica gel plates through elastic films; limiting springs are fixed to the upper ends of multiple supporting cylinders, and medical pull ropes are arranged in the multiple supporting cylinders in a sliding mode; liquid suction cavities are formed in the multiple arc-shaped silica gel plates, the multiple liquid suction cavities communicate with one another, and liquid suction holes are formed in the inner side walls of the multiple liquid suctioncavities; a sewage suction tube is inserted into the supporting tube; and the secondary pollution of residual bloody tissues to the bladder of a patient is prevented, and the safety risk of the patient after rehabilitation is reduced.

The invention aims to provide a prostate intracavity thermal therapy catheter which can perform self-adaptive size adjustment on the heating balloon according to the inner diameter of the urethra of apatient. In order to achieve the purpose, the prostate intracavity thermal therapy catheter comprises a tube body, a positioning balloon and a thermal therapy balloon. A first balloon cavity channel,a backflow cavity channel and a wiring cavity channel are formed in the tube body. The positioning balloon is arranged on the outer side of the tube body and communicated with the first balloon cavity, and gas or liquid can be filled into the positioning balloon from the first balloon cavity. The thermal therapy balloon is arranged on the outer side of the catheter body, a thermal therapy assembly is arranged in the thermal therapy balloon, and wires connected to the thermal therapy assembly are arranged in the wiring cavity. The backflow cavity channel is communicated with the positioning balloon and the thermal therapy balloon, and inflated gas or liquid circulates between the positioning balloon and the thermal therapy balloon through the backflow cavity channel, so that pressure balance in the positioning balloon and the thermal therapy balloon is kept, and the thermal therapy balloon is inflated and expanded to a size suitable for being attached to the inner wall of the urethra.

The invention discloses a method for detecting damage of mitochondria in prostate gland cells. The method comprises the following detection steps: extracting 1-2ml of prostatic fluid, adding the prostatic fluid into a sample bottle filled with a buffer solution, and sequentially adding 1ml of a reagent A and 1ml of a reagent B into the sample bottle; and uniformly mixing, observing color change in 2 minutes, comparing the color change with a colorimetric plate, thus obtaining a detection result. The method is simple, practical, quick and high in sensitivity.

The invention belongs to the technical field of medical treatment instruments, and specifically relates to a coaxial prostate dilating device. The coaxial prostate dilating device comprises a catheter, wherein a saccule is arranged at the front part of the catheter, and the catheter is further sleeved with a cannula; the saccule is completely coated with the cannula when the cannula slides to thefront part of the catheter; and the saccule is completely exposed outside when the cannula slides to the rear part of the catheter. By virtue of a coaxial catheter design, the coaxial prostate dilating device is formed through coaxial nesting combination of the outer-layer cannula and the catheter, the cannula sleeves the saccule, and the head end of the catheter is integrally linked with the cannula in a smooth transition manner, so that a tube body structure is smooth and is easy to insert.

The invention discloses a prostatic cancer tumor marker detection method based on molybdenum disulfide/nano platinum-coated triangle/polydopamine. The method comprises the following steps of adsorbing molybdenum disulfide on the surface of a carbon working electrode, covalently linking the carbon working electrode with nano platinum-coated triangle, and carrying out electropolymerization on the surface to form a polydopamine film layer; fixing the total prostate specific antigen t-PSA and free prostate specific antigen f-PSA antibodies on a modified electrode to form a sensitive electrode, and realizing the prostatic cancer detection by using a result and a concentration ratio. According to the present invention, the characteristics of molybdenum disulfide surface area, biocompatibility, structural functionality and the like are utilized, and the nano platinum-coated triangle has the unique catalytic performance, so that the electrochemical performance of the electrode is enhanced under the combined action; a large number of functional groups on the surface of the polydopamine film are used for providing multiple sites for specific antigens, so that the biological sensitivity of the electrode is improved; t-PSA and f-PSA are detected by the specific combination of the antigen and the antibody, and the high-precision detection of the prostatic cancer is realized by using a result and a concentration ratio.

The invention provides a five-cavity four-balloon prostate expansion catheter assembly (100). The five-cavity four-balloon prostate expansion catheter assembly comprises a catheter (10) and a latex sleeve (30), the guide pipe (10) comprises four communicating pipes; four liquid outlets are formed in the wall surface of the guide pipe (10); one ends of the four communicating pipes are respectivelycommunicated with the four liquid outlets; wherein the latex sleeve (30) is combined with the catheter (10); an outer cavity (51), an inner cavity (52), a first auxiliary cavity (53) and a second auxiliary cavity (57) which are isolated from one another are formed between the latex sleeve (30) and the catheter (10), the outer cavity (51) surrounds the inner cavity (52), and the inner cavity (52),the outer cavity (51), the first auxiliary cavity (53) and the second auxiliary cavity (57) communicate with the four liquid outlets correspondingly. According to the five-cavity four-balloon prostateexpansion catheter assembly, prostatic hyperplasia diseases can be effectively treated.

The invention provides a traditional Chinese medicine (TCM) for treating prostatic hyperplasia, belonging to the field of TCMs for treating diseases of urinary system. The TCM has good effect and quick effect. The TCM is prepared from the following raw materials: yerbadetajo herb, angelica, lucid ganoderma, salvia miltiorrhiza, pseudo-ginseng, pink herb, gardenia and the like, has the functions of strengthening the body resistance, invigorating qi and nourishing blood, activating blood circulation to dissipate blood stasis, inducing diuresis to alleviate edema and excreting dampness for treating stranguria and has the advantages of obvious effect, definite efficacy and quicker effect.